Dian Diagnostics Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 26, 2022 at 07:35 am EDT
Share
Dian Diagnostics Group Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 4,648.82 million compared to CNY 2,868.27 million a year ago. Revenue was CNY 4,648.82 million compared to CNY 2,868.27 million a year ago. Net income was CNY 753.71 million compared to CNY 338.56 million a year ago. Basic earnings per share from continuing operations was CNY 1.2148 compared to CNY 0.5457 a year ago. Diluted earnings per share from continuing operations was CNY 1.209 compared to CNY 0.5419 a year ago.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.